UNSPSC 51203402: Cladribine

This classification denotes a radiosensitizing agent and purine antagonist with the molecular formula C10H12ClN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 47M74X9YT5, chemically known as adenosine, 2-chloro-2-deoxy- but more generally known as cladribine, which bears US NIH Compound Identifier 1546. European Medicines Agency schedules Cladribine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06635MIG.

UNSPSC 51203402 Cladribine, a Commodity code, nominally describes a specific pharmaceutical product, but recent state and local opportunities tagged under this code show minimal actual procurement of cladribine itself. Instead, the code has been applied to a wide range of pharmaceutical and medical supply solicitations, including naloxone and drug deactivation systems, emergency medical and first aid supplies for fire departments, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and therapeutic pharmacy initiative programs. State and local issuing bodies pursuing opportunities under this code span county health departments, municipal fire departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work being solicited is substantially broader than the code's nominal scope—health systems and emergency services are acquiring diverse pharmaceutical inventory, medical consumables, and pharmacy benefit management capabilities rather than cladribine specifically.

Recent activity appears concentrated in Florida and Minnesota, with Texas involvement in preliminary market research. Representative opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 and an SLBE set-aside (26P00145, due March 13, 2026), the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products serving state and local facilities across multiple states including Oregon (S1070000015802, due March 26, 2026), and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026). The mismatch between the code's nominal pharmaceutical specificity and the broad medical-supply activity tagged under it suggests that state and local procurement systems are using this code loosely for health-sector purchasing rather than cladribine-specific procurement.